John A Adeniyi, M.D., F.A.C.S. Radiology - Vascular & Interventional Radiology Medicare: Accepting Medicare Assignments Practice Location: 527 Medical Park Dr Ste 501, Bridgeport, WV 26330 Phone: 304-842-3993 Fax: 304-842-4083 |
News Archive
Immunological research at the University of Haifa, Israel, has made a new breakthrough, revealing a critical component in the "decision-making" process of white blood cells that play a role in the healing process from bacterial inflammation.
The human brain is bombarded with all kinds of information, from the memory of last night's delicious dinner to the instructions from your boss at your morning meeting. But how do you "tune in" to just one thought or idea and ignore all the rest of what is going on around you, until it comes time to think of something else?
In a study that included children and young adults with relapsed or refractory cancer, incorporation of integrative clinical genomic sequencing data into clinical management was feasible, revealed potentially actionable findings in nearly half of the patients, and was associated with change in treatment and family genetics counseling for a small proportion of patients, according to a study in the September 1 issue of JAMA.
Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.
› Verified 5 days ago